Temporal analysis of expression of XNR1 at the lateral plate mesoderm (LPM) following ectopic expression of XCR2
| . | . | . | XNR1 expression in the LPM . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Injection side . | Stage . | No signal . | Left (normal) . | Bilateral . | Right (invert) . | Total . | |||
| Uninjected | 13/14 | 100% | 0% | 0% | 0% | 48 | ||||
| 15 | 100% | 0% | 0% | 0% | 24 | |||||
| 16/17 | 100% | 0% | 0% | 0% | 50 | |||||
| 18/19 | 100% | 0% | 0% | 0% | 58 | |||||
| 20 | 0% | 100% | 0% | 0% | 15 | |||||
| 21/22/23 | 2% | 96% | 2% | 0% | 56 | |||||
| 24/25 | 0% | 100% | 0% | 0% | 15 | |||||
| pCS-EGFP | Left | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Left | 15 | 100% | 0% | 0% | 0% | 20 | ||||
| Left | 16/17 | 100% | 0% | 0% | 0% | 30 | ||||
| Left | 18/19 | 100% | 0% | 0% | 0% | 30 | ||||
| Left | 20 | 13% | 80% | 0% | 7% | 15 | ||||
| Left | 21/22/23 | 11% | 95% | 0% | 0% | 38 | ||||
| Left | 24/25 | 0% | 100% | 0% | 0% | 12 | ||||
| pCS-EGFP | Right | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Right | 15 | 100% | 0% | 0% | 0% | 20 | ||||
| Right | 16/17 | 100% | 0% | 0% | 0% | 30 | ||||
| Right | 18/19 | 100% | 0% | 0% | 0% | 30 | ||||
| Right | 20 | 13% | 88% | 0% | 0% | 16 | ||||
| Right | 21/22/23 | 5% | 93% | 0% | 2% | 44 | ||||
| Right | 24/25 | 0% | 90% | 10% | 0% | 10 | ||||
| pCS-XCR2 | Left | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Left | 15 | 76% | 24% | 0% | 0% | 25 | ||||
| Left | 16/17 | 47% | 53% | 0% | 0% | 30 | ||||
| Left | 18/19 | 13% | 87% | 0% | 0% | 30 | ||||
| Left | 20 | 7% | 93% | 0% | 0% | 15 | ||||
| Left | 21/22/23 | 0% | 96% | 4% | 0% | 45 | ||||
| Left | 24/25 | 7% | 93% | 0% | 0% | 15 | ||||
| pCS-XCR2 | Right | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Right | 15 | 83% | 0% | 0% | 17% | 29 | ||||
| Right | 16/17 | 43% | 0% | 0% | 57% | 30 | ||||
| Right | 18/19 | 17% | 0% | 0% | 83% | 30 | ||||
| Right | 20 | 0% | 7% | 27% | 67% | 15 | ||||
| Right | 21/22/23 | 2% | 4% | 73% | 20% | 45 | ||||
| Right | 24/25 | 7% | 20% | 27% | 47% | 15 | ||||
| . | . | . | XNR1 expression in the LPM . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Injection side . | Stage . | No signal . | Left (normal) . | Bilateral . | Right (invert) . | Total . | |||
| Uninjected | 13/14 | 100% | 0% | 0% | 0% | 48 | ||||
| 15 | 100% | 0% | 0% | 0% | 24 | |||||
| 16/17 | 100% | 0% | 0% | 0% | 50 | |||||
| 18/19 | 100% | 0% | 0% | 0% | 58 | |||||
| 20 | 0% | 100% | 0% | 0% | 15 | |||||
| 21/22/23 | 2% | 96% | 2% | 0% | 56 | |||||
| 24/25 | 0% | 100% | 0% | 0% | 15 | |||||
| pCS-EGFP | Left | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Left | 15 | 100% | 0% | 0% | 0% | 20 | ||||
| Left | 16/17 | 100% | 0% | 0% | 0% | 30 | ||||
| Left | 18/19 | 100% | 0% | 0% | 0% | 30 | ||||
| Left | 20 | 13% | 80% | 0% | 7% | 15 | ||||
| Left | 21/22/23 | 11% | 95% | 0% | 0% | 38 | ||||
| Left | 24/25 | 0% | 100% | 0% | 0% | 12 | ||||
| pCS-EGFP | Right | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Right | 15 | 100% | 0% | 0% | 0% | 20 | ||||
| Right | 16/17 | 100% | 0% | 0% | 0% | 30 | ||||
| Right | 18/19 | 100% | 0% | 0% | 0% | 30 | ||||
| Right | 20 | 13% | 88% | 0% | 0% | 16 | ||||
| Right | 21/22/23 | 5% | 93% | 0% | 2% | 44 | ||||
| Right | 24/25 | 0% | 90% | 10% | 0% | 10 | ||||
| pCS-XCR2 | Left | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Left | 15 | 76% | 24% | 0% | 0% | 25 | ||||
| Left | 16/17 | 47% | 53% | 0% | 0% | 30 | ||||
| Left | 18/19 | 13% | 87% | 0% | 0% | 30 | ||||
| Left | 20 | 7% | 93% | 0% | 0% | 15 | ||||
| Left | 21/22/23 | 0% | 96% | 4% | 0% | 45 | ||||
| Left | 24/25 | 7% | 93% | 0% | 0% | 15 | ||||
| pCS-XCR2 | Right | 13/14 | 100% | 0% | 0% | 0% | 30 | |||
| Right | 15 | 83% | 0% | 0% | 17% | 29 | ||||
| Right | 16/17 | 43% | 0% | 0% | 57% | 30 | ||||
| Right | 18/19 | 17% | 0% | 0% | 83% | 30 | ||||
| Right | 20 | 0% | 7% | 27% | 67% | 15 | ||||
| Right | 21/22/23 | 2% | 4% | 73% | 20% | 45 | ||||
| Right | 24/25 | 7% | 20% | 27% | 47% | 15 | ||||
40 pg of plasmids were injected with 0.5 ng of EGFP RNA into the marginal region of one blastomere at the two-cell stage. Embryos were fixed at various stages and analyzed for XNR1 expression by in situ hybridization.